J&J Offers To Help Shape Terms Of CMS Practical Clinical Trial Agenda
This article was originally published in The Gray Sheet
Executive Summary
Industry should work with CMS to establish a priority list to determine which technologies are best suited for practical clinical trials (PCTs), according to Johnson & Johnson VP-Health Policy & Government Affairs Kathy Buto
You may also be interested in...
PET/Alzheimer’s Study To Be First CMS-Funded Practical Clinical Trial – Tunis
CMS plans to release a position paper on new and ongoing initiatives related to improving the quality of clinical evidence, according to Chief Medical Officer Sean Tunis, MD
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.